Allegro DVT Fosters Adoption of MPEG-5 LCEVC Video Codec, Releases a Full Range of LCEVC Products
31.8.2023 16:00:00 EEST | Business Wire | Press release
Allegro DVT, a leading provider of Video codec compliance streams and silicon video IP solutions has launched a complete range of MPEG-5 LCEVC products comprising LCEVC compliance streams and LCEVC hardware decoder and encoder video IPs (D301 and E301).
Allegro DVT’s LCEVC Compliance Streams are crucial to confirm that decoder implementations adhere to the LCEVC standard. They are used by all companies developing SoCs or devices with LCEVC decoding capabilities.
Furthermore, Allegro DVT is also releasing its E301 LCEVC Encoding HW IP which complements its D301 LCEVC Decoding HW IP that was previously announced at NAB in April 2023. This full range of LCEVC HW IPs is suitable for integration into SoCs/ASICs requiring HW based support for LCEVC encoding and decoding functions.
The E301 is the industry’s first LCEVC encoding IP solution and was developed in close collaboration with V-Nova, the inventor of the LCEVC technology. It is optimized for power and silicon area, allows system-on-chip (SoC) and ASIC designers to easily integrate LCEVC encoding into their products. It supports picture resolution up to 8K, pixel widths from 8 to 12-bits and chroma subsampling formats ranging from 4:2:0 up to 4:4:4. The IP also features fast and easy SoC integration and is delivered with full user configurable control software.
Guido Meardi, CEO of V-Nova commented “As LCEVC continues its progression in the industry, a holistic suite of hardware IP tools including decoding, encoding, and verification platforms had become essential. Allegro DVT's offerings are perfectly timed to meet this emerging trend, reinforcing the momentum behind LCEVC. Their products will not only fuel LCEVC's adoption but also cement its position as a transformative force that many are already integrating into their plans.”
Nouar Hamze, CEO of Allegro DVT added “With today’s announcement, Allegro DVT has truly become a one-stop-shop for SoC/ASIC designers who need to rapidly add LCEVC encoding/decoding function into their products. Our E301 LCEVC Encoding IP, developed and benchmarked in collaboration with V-Nova, produces the best encoding video quality that fully unlocks the potential of the LCEVC technology. Together with our D301 LCEVC Decoding IP and LCEVC compliance streams, we are enabling an easy and seamless path for SoCs/ASIC companies to integrate and verify the new LCEVC standard into their products, giving them a tremendous competitive advantage.”
MPEG-5 part 2 LCEVC (Low Complexity Enhancement Video Coding) is the latest standard by MPEG and ISO. Instead of replacing existing codecs, LCEVC enhances them, reducing both costs and energy consumption of the transcoding process by up to 70%. Remarkably, it also augments compression efficiency by up to 40%, with benefits that stack upon those of other methods to improve video compression, rather than being an alternative. It specifies an enhancement layer which, when combined with a base video encoded with a separate codec, produces an enhanced video stream. LCEVC also enables unique benefits in applications such as single-stream SDR-HDR backward-compatible delivery and low-latency video delivery.
To find out more about Allegro DVT’s LCEVC products, come and visit Allegro DVT booth 5.A25 at IBC Amsterdam 15-18 September 2023.
About Allegro DVT
Allegro DVT is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on H.264, HEVC, VP9, AV1, VVC and LCEVC standards.
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 700 international patents, along with a range of software products and solutions.
For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831702100/en/
Contact information
Allegro DVT press:
Stéphanie Nastasi – Communication Manager
marcom@allegrodvt.com
V-Nova press:
Jose D. Guariglia – PR Account Manager, Bubble UK and EMEA
jd@bubbleagency.com
Casey Love – PR Account Manager, Bubble USA
caseyl@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we see an opportunity to bring decision-makers closer to insight and reduce the manual effort between data and action," said Rishi Padhi, SVP and Chief Digital and Information
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 13:18:00 EEST | Press release
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan. Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patie
Zoom Advances Its AI Strategy With a New Unified Context Layer That Helps Turn Meeting Conversations Into Completed Work22.10.2026 13:13:00 EEST | Press release
Today at its annual Zoomtopia customer conference, Zoom Communications, Inc. (NASDAQ: ZM), a leading AI-first platform for human connection, introduced a new Unified Context Layer and several new products with AI-powered capabilities. The new offerings are designed to help businesses transform rich meeting context into meaningful deliverables that help accelerate work outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021498160/en/ Business conversations drive critical decisions and build customer history every day. A customer interaction might start in a meeting, continue by phone, and carry on in chat threads. But when that context is scattered across applications, people, and AI agents lose the thread, and teams spend significant time piecing together what happened, when it happened, and what they should do about it. Zoom’s new Unified Context Layer helps close that gap by linking conversation history with releva
TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release
TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom